New Zealand Pharmaceuticals and Healthcare Report Q2 2016

75 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: The free reign that New Zealand’s Pharmaceutical Management Agency (PHARMAC) has over
pharmaceutical spending will come under pressure. While the agency’s stringent approach to listing
medicines has helped to curtail drug spending, it has limited access to novel ‘first-in-class’ medicines. This
in turn has created public pressure from both patient groups and politicians that could infringe upon
PHARMAC’s operations. The Trans-Pacific Partnership will also have ramifications on the agency as
stronger biologic protection delays the introduction of biosimilars.
Headline Expenditure Forecasts
? Pharmaceuticals: NZD1.48bn (USD1.0bn) in 2015 to NZD1.51bn (USD932mn) in 2016; 2.0% in local
currency terms and -9.8% in US dollar terms.
? Healthcare: NZD23.09bn (USD16.11bn) in 2015 to NZD23.63bn (USD14.58bn) in 2016; 2.4% in local
currency terms and -9.5% in US dollar terms.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (New Zealand 2014-2020) 7
SWOT 9
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (New Zealand 2012-2020) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012-2020) 14
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012-2020) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012-2020) 15
Prescription Drug Market Forecast 16
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020) 17
Patented Drug Market Forecast 18
Table: Patented Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020) 19
Generic Drug Market Forecast 20
Table: Generic Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020) 21
OTC Medicine Forecast 22
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020) 23
Pharmaceutical Trade Forecast 24
Table: Pharmaceutical Trade Data And Forecasts (New Zealand 2014-2020) 25
Table: Pharmaceutical Trade Data And Forecasts local currency (New Zealand 2014-2020) 25
Industry Risk Reward Index 26
Asia Pacific Risk/Reward Index 26
New Zealand Risk/Reward Index 32
Rewards 32
Risks 32
Regulatory Review 34
Regulatory Development 34
Intellectual Property Issues 34
Pricing & Reimbursement Regime 35
Table: Top 20 Medicines By Ex-Manufacturer Cost To PHARMAC In The Year Ending June 2010 (NZDmn) 40
Table: Top 20 Medicines Reimbursed By PHARMAC According To Prescription Numbers In The Year Ending June 2010 41
Market Overview 43
Healthcare Sector 44
Table: Healthcare Resources (New Zealand 2010-2015) 45
Table: Healthcare Activity (New Zealand 2010-2015) 46
Table: Healthcare Personnel (New Zealand 2010-2015) 46
Research & Development 47
Clinical Trials 47
Epidemiology 49
Competitive Landscape 53
Research-Based Industry 53
Table: Multinational Market Activity 54
Pharmaceutical Distribution 54
Pharmaceutical Retail Sector 55
Company Profile 57
Douglas Pharmaceuticals 57
New Zealand Pharmaceuticals 60
Pfizer New Zealand 62
Demographic Forecast 64
Table: Population Headline Indicators (New Zealand 1990-2025) 65
Table: Key Population Ratios (New Zealand 1990-2025) 65
Table: Urban/Rural Population & Life Expectancy (New Zealand 1990-2025) 66
Table: Population By Age Group (New Zealand 1990-2025) 66
Table: Population By Age Group % (New Zealand 1990-2025) 67
Glossary 69
Methodology 71
Pharmaceutical Expenditure Forecast Model 71
Healthcare Expenditure Forecast Model 71
Notes On Methodology 72
Risk/Reward Index Methodology 73
Index Overview 74
Table: Pharmaceutical Risk/Reward Index Indicators 74
Indicator Weightings 75

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (New Zealand 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (New Zealand 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2012-2020)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (New Zealand 2012-2020)
Table: Pharmaceutical Trade Data And Forecasts (New Zealand 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (New Zealand 2014-2020)
Table: Top 20 Medicines By Ex-Manufacturer Cost To PHARMAC In The Year Ending June 2010 (NZDmn)
Table: Top 20 Medicines Reimbursed By PHARMAC According To Prescription Numbers In The Year Ending June 2010
Table: Healthcare Resources (New Zealand 2010-2015)
Table: Healthcare Activity (New Zealand 2010-2015)
Table: Healthcare Personnel (New Zealand 2010-2015)
Table: Multinational Market Activity
Table: Population Headline Indicators (New Zealand 1990-2025)
Table: Key Population Ratios (New Zealand 1990-2025)
Table: Urban/Rural Population & Life Expectancy (New Zealand 1990-2025)
Table: Population By Age Group (New Zealand 1990-2025)
Table: Population By Age Group % (New Zealand 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

  • Kuwait Pharmaceuticals and Healthcare Report Q3 2015BMI View: While the losses incurred by Yiaco, the largest drug distributor in Kuwait, highlight a deteriorated near-term operating environment, with markedly lower prices as a result of the ongoing Gulf Cooperation Council (GCC) medicine price unification process, drugmakers will continue to perceive high long-run returns. Exhibiting a high and very costly burden of diabetes and cardiovascular conditions, Kuwait's aging population will continue to receive rising access to quality […]
  • New Zealand Pharmaceuticals and Healthcare Report Q1 2016BMI View: New Zealand's updated Health Strategy draft will see limited improvement to the challenging business environment for innovative drugmakers. Cost minimisation continues to be a key aspect of the approach adopted, with the Pharmaceutical Management Agency maintaining its dominant role in curbing pharmaceutical spending. Nonetheless, there will be opportunities for other segments of the health industry, such as telecare, which is poised to play a critical role in enabling New […]
  • India Pharmaceuticals and Healthcare Report Q2 2016BMI View: The shift in the pharmaceutical landscape due to the Trans-Pacific Partnership (TPP) will be negative for the Indian generic drug industry. Collectively accounting for 40% of medicine exports from India, the 12 member markets of the TPP will see stronger patent protection and longer regulatory data protection. This coupled with the introduction of a patent linkage system will serve to deter the introduction of Indian generic drugs and curtail their overall growth. Headline […]
  • Malaysia Pharmaceuticals and Healthcare Report Q2 2016BMI View: We hold a bullish outlook for Malaysia's pharmaceutical market over our forecast period. We believe the government's commitment to expanding healthcare access coupled with the country's growing population and disease burden will drive medicine demand in the coming years. Furthermore, the signing of the Trans-Pacific Partnership (TPP) agreement - after years of negotiation and uncertainty - will work to strengthen multinational interest in the market, particularly patented […]
  • Morocco Pharmaceuticals and Healthcare Report Q2 2016BMI View: We hold an optimistic outlook for the Moroccan pharmaceutical market despite the economic slowdown over 2016. We expect the government's increasing efforts to improve healthcare coverage coupled with the country's growing non-communicable disease burden will drive the demand for medicines in long-term. A major downside risk to our forecast is the uncertainty surrounding drug prices as a result of price cuts and increased taxation on medicines in recent years, which will […]